Biological and Genetic Features of Neuroblastoma and Their Clinical Importance - PubMed

Review

Biological and Genetic Features of Neuroblastoma and Their Clinical Importance

Nevim Aygun. Curr Pediatr Rev. 2018.

Abstract

Neuroblastoma derived from primitive cells of the sympathetic nervous system typically develops in the adrenal medulla or paraspinal ganglia. Neuroblastoma usually occurs sporadically, but familial cases are also observed. ALK and PHOX2B germline mutations can cause hereditary neuroblastoma, while a common genetic variation in chromosome 6p22 is associated to sporadic neuroblastoma. However, the aetiology of sporadic neuroblastoma is not exactly known. This embryonic malignancy generally represents the second most common solid tumour after central nervous system tumours throughout the world in childhood. Neuroblastoma is a complex disease that has different clinical courses, from metastatic spread to spontaneous regression. Spontaneous regression can occur without therapy in primary or metastatic site. Potential regression mechanisms primarily involve apoptosis, hypermethylation of subtelomeric DNA, immune response and Nerve Growth Factor (NGF) deprivation. Neuroblastoma is a heterogeneous tumour that can show many different chromosomal abnormalities; e.g. MYCN amplification, 1p deletion, unbalanced translocations involving chromosome 17, aneuploidies and Loss of Heterozygosity (LOH) events. Tyrosine kinase receptors TrkA, TrkB and TrkC, their ligands NGF, Brain-derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3), and Aurora Kinase A (AURKA) play a regulatory role in differentiation, apoptosis, cell proliferation, tumourigenesis, angiogenesis or metastasis of neuroblastoma. TrkA expression is associated with differentiation or regression, depending on presence or absence of NGF, whereas TrkB and BDNF are mostly expressed in aggressive neuroblastomas with MYCN amplification. MYCN is amplified in 18-38% of neuroblastoma cases. MYCN amplification mechanism remains to be completely clarified. This paper reviews the biological/genetic features and their clinical importance in neuroblastoma.

Keywords: Neuroblastoma; biological and genetic features; cell behaviour; cell signalling pathways; chromosomal abnormalities; clinical behaviour; clinical importance; genomic signature..

Similar articles

• Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma.

  Eggert A, Ikegaki N, Liu XG, Brodeur GM. Eggert A, et al. Klin Padiatr. 2000 Jul-Aug;212(4):200-5. doi: 10.1055/s-2000-9677. Klin Padiatr. 2000. PMID: 10994551

• Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.

  Rydén M, Sehgal R, Dominici C, Schilling FH, Ibáñez CF, Kogner P. Rydén M, et al. Br J Cancer. 1996 Sep;74(5):773-9. doi: 10.1038/bjc.1996.435. Br J Cancer. 1996. PMID: 8795581 Free PMC article.

• Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis.

  Krona C, Carén H, Sjöberg RM, Sandstedt B, Laureys G, Kogner P, Martinsson T. Krona C, et al. Int J Oncol. 2008 Mar;32(3):575-83. Int J Oncol. 2008. PMID: 18292934

• Trk receptor expression and inhibition in neuroblastomas.

  Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE. Brodeur GM, et al. Clin Cancer Res. 2009 May 15;15(10):3244-50. doi: 10.1158/1078-0432.CCR-08-1815. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417027 Free PMC article. Review.

Cited by

• Association of Image-Defined Risk Factors with Clinical, Biological Features and Outcome in Neuroblastoma.

  Laura B, Radu B, Patricia C, Andreea M. Laura B, et al. Children (Basel). 2022 Nov 8;9(11):1707. doi: 10.3390/children9111707. Children (Basel). 2022. PMID: 36360435 Free PMC article.

• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

  Candido MF, Medeiros M, Veronez LC, Bastos D, Oliveira KL, Pezuk JA, Valera ET, Brassesco MS. Candido MF, et al. Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664. Pharmaceutics. 2023. PMID: 36839989 Free PMC article. Review.

• Anticancer Efficacy and Mechanisms of a Dual Targeting of Norepinephrine Transporter and Thyrointegrin αvβ3 Antagonist in Neuroblastoma.

  Godugu K, Karakus OO, Fujioka K, Glinsky GV, Mousa SA. Godugu K, et al. J Cancer. 2022 May 16;13(8):2594-2606. doi: 10.7150/jca.72522. eCollection 2022. J Cancer. 2022. PMID: 35711848 Free PMC article.

• Advances in liquid biopsy in neuroblastoma.

  Zhuo Z, Lin L, Miao L, Li M, He J. Zhuo Z, et al. Fundam Res. 2022 Aug 17;2(6):903-917. doi: 10.1016/j.fmre.2022.08.005. eCollection 2022 Nov. Fundam Res. 2022. PMID: 38933377 Free PMC article. Review.

• NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma.

  Juvvuna PK, Mondal T, Di Marco M, Kosalai ST, Kanduri M, Kanduri C. Juvvuna PK, et al. Neurooncol Adv. 2021 Apr 9;3(1):vdab056. doi: 10.1093/noajnl/vdab056. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34056606 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Bentham Science Publishers Ltd.
  • Ingenta plc

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal